Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CDC25C | P30307 | 5/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917644 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL29362116 | 0.89 | CDC25C (1.00) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL4247040 | 0.86 | MEN1 (0.75) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL1917474 | 0.83 | CDC25C (1.00) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL1916880 | 0.83 | CDC25C (1.00) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL1917318 | 0.83 | CDC25C (1.00) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL6080522 | 0.82 | MEN1 (0.68) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL6434785 | 0.76 | CDC25C (0.61) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL1917276 | 0.76 | CDC25C (0.78) | MEN1KMT2ATHRBAPEX1RECQL | |
| SCHEMBL3153190 | 0.76 | CDC25C (0.67) | MEN1KMT2ATHRBAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | Cartesian Therapeutics Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CARTESIAN THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4568750-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | Cartesian Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12324826-B2 | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates | JOMOCO, CORP. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250177360-A1 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE | CARTESIAN THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119700983-A | Application of UBR5 in preparation of medicines for treating pigment dermatosis | 中南大学湘雅医院 | 2025-03-28 | — | — | CN | disclosed |
| EP-3858348-B1 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS | CARTESIAN THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-118987263-A | Methods and compositions for enhancing CD4+ regulatory T cells | 西莱克塔生物科技公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024229350-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS FOR DIABETES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229370-A1 | COMPOSITIONS AND METHODS FOR TREATING GVHD | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2022150335-A1 | VIRAL VECTOR DOSING PROTOCOLS | SELECTA BIOSCIENCES, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022098901-A1 | COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | SELECTA BIOSCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133864-A1 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | SELECTA BIOSCIENCES INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114306638-A | Controlled release of immunosuppressants from synthetic nanocarriers | 西莱克塔生物科技公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11298342-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity | SELECTA BIOSCIENCES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220071968-A1 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3962537-A1 | METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS | Selecta Biosciences, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114146167-A | Methods and compositions for attenuating gene expression modulating antiviral transfer vector immune responses | 西莱克塔生物科技公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114126666-A | Methods for treating subjects with pre-existing immunity to viral transfer vectors | 西莱克塔生物科技公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11235057-B2 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses | SELECTA BIOSCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133864-A1 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | FCGR3B, SERPINB1, SERPINA6 | MEN1 4778/4885KMT2A 4076/4885THRB 4872/4885 |
| US-20250177360-A1 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE | SERPINA6, FCGRT, FCGR3B | MEN1 2347/4885KMT2A 4326/4885THRB 4751/4885 |
| US-11235057-B2 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses | CD47, LY96, CD74 | MEN1 4151/4885KMT2A 2983/4885THRB 4824/4885 |
| US-11298342-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity | CD74, HLA-DRB1, MSR1 | MEN1 3626/4885KMT2A 4141/4885THRB 4287/4885 |
| US-20220071968-A1 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | IL2, CD74, HLA-DRB1 | MEN1 2216/4885KMT2A 3894/4885THRB 4785/4885 |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | HLA-C, CPA3, HLA-A | MEN1 3722/4885KMT2A 2366/4885THRB 4761/4885 |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CD74, CCR1, MSR1 | MEN1 2696/4885KMT2A 4152/4885THRB 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.